The Filings Report

Encompass Health Corporation Common Stock

EHCNYSECIK 785161Healthcare / Healthcare Providers & Servicesfiscal year ends December70 quarters since 2009

Revenue, Q3 FY2026
$1.6B
+8.9% on Q3 FY2025
Net income
$150M
+18.5% on Q3 FY2025
Free cash flow
—
no year-earlier figure
Diluted EPS
$1.50
+21.0% on Q3 FY2025
Revenue, TTM
$6.3B
trailing four quarters
Net margin, TTM
10.2%
net income $644M
Free cash flow, TTM
—
Cash and equivalents
$76M
long-term debt —, Sep 30, 2026
Shares, 12-month change
−2.5%
98M shares, Sep 30, 2026
Buybacks, TTM
$280M
2.1% of market value
Dividends, TTM
$77M
0.6% of market value
Market value
$13.5B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 3, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Encompass Health Corporation Common Stock reported revenue of $1.6B, +8.9% on Q3 FY2025, and net income of $150M (+18.5%). Diluted earnings per share were $1.50.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 3, 2026.

Revenue and net incomeRevenueNet income
$0$500M$1.0B$1.5B$2.0BQ4'22, Revenue: $1.1BQ4'22, Net income: $89MQ4'22Q1'23, Revenue: $1.2BQ1'23, Net income: $88MQ1'23Q2'23, Revenue: $1.2BQ2'23, Net income: $91MQ2'23Q3'23, Revenue: $1.2BQ3'23, Net income: $85MQ3'23Q4'23, Revenue: $1.2BQ4'23, Net income: $88MQ4'23Q1'24, Revenue: $1.3BQ1'24, Net income: $113MQ1'24Q2'24, Revenue: $1.3BQ2'24, Net income: $114MQ2'24Q3'24, Revenue: $1.4BQ3'24, Net income: $108MQ3'24Q4'24, Revenue: $1.4BQ4'24, Net income: $121MQ4'24Q1'25, Revenue: $1.5BQ1'25, Net income: $152MQ1'25Q2'25, Revenue: $1.5BQ2'25, Net income: $142MQ2'25Q3'25, Revenue: $1.5BQ3'25, Net income: $127MQ3'25Q4'25, Revenue: $1.5BQ4'25, Net income: $146MQ4'25Q1'26, Revenue: $1.6BQ1'26, Net income: $195MQ1'26Q2'26, Revenue: $1.6BQ2'26, Net income: $154MQ2'26Q3'26, Revenue: $1.6BQ3'26, Net income: $150MQ3'26$0$500M$1.0B$1.5B$2.0BQ4'22, Revenue: $1.1BQ4'22, Net income: $89MQ1'23, Revenue: $1.2BQ1'23, Net income: $88MQ1'23Q2'23, Revenue: $1.2BQ2'23, Net income: $91MQ3'23, Revenue: $1.2BQ3'23, Net income: $85MQ3'23Q4'23, Revenue: $1.2BQ4'23, Net income: $88MQ1'24, Revenue: $1.3BQ1'24, Net income: $113MQ1'24Q2'24, Revenue: $1.3BQ2'24, Net income: $114MQ3'24, Revenue: $1.4BQ3'24, Net income: $108MQ3'24Q4'24, Revenue: $1.4BQ4'24, Net income: $121MQ1'25, Revenue: $1.5BQ1'25, Net income: $152MQ1'25Q2'25, Revenue: $1.5BQ2'25, Net income: $142MQ3'25, Revenue: $1.5BQ3'25, Net income: $127MQ3'25Q4'25, Revenue: $1.5BQ4'25, Net income: $146MQ1'26, Revenue: $1.6BQ1'26, Net income: $195MQ1'26Q2'26, Revenue: $1.6BQ2'26, Net income: $154MQ3'26, Revenue: $1.6BQ3'26, Net income: $150MQ3'26

Net income losses drawn in red.

Free cash flow
−$50M$0$50M$100M$150MQ4'22, Free cash flow: −$37MQ4'22Q1'23, Free cash flow: $128MQ1'23Q2'23, Free cash flow: $85MQ2'23Q3'23Q4'23Q1'24Q2'24Q3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26−$50M$0$50M$100M$150MQ4'22, Free cash flow: −$37MQ1'23, Free cash flow: $128MQ1'23Q2'23, Free cash flow: $85MQ3'23Q1'24Q3'24Q1'25Q3'25Q1'26Q3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$50M$100M$150M$200MQ4'22, Cash and equivalents: $22MQ4'22Q1'23, Cash and equivalents: $85MQ1'23Q2'23, Cash and equivalents: $118MQ2'23Q3'23, Cash and equivalents: $100MQ3'23Q4'23, Cash and equivalents: $69MQ4'23Q1'24, Cash and equivalents: $134MQ1'24Q2'24, Cash and equivalents: $154MQ2'24Q3'24, Cash and equivalents: $148MQ3'24Q4'24, Cash and equivalents: $85MQ4'24Q1'25, Cash and equivalents: $96MQ1'25Q2'25, Cash and equivalents: $99MQ2'25Q3'25, Cash and equivalents: $49MQ3'25Q4'25, Cash and equivalents: $72MQ4'25Q1'26, Cash and equivalents: $111MQ1'26Q2'26, Cash and equivalents: $108MQ2'26Q3'26, Cash and equivalents: $76MQ3'26$0$50M$100M$150M$200MQ4'22, Cash and equivalents: $22MQ1'23, Cash and equivalents: $85MQ1'23Q2'23, Cash and equivalents: $118MQ3'23, Cash and equivalents: $100MQ3'23Q4'23, Cash and equivalents: $69MQ1'24, Cash and equivalents: $134MQ1'24Q2'24, Cash and equivalents: $154MQ3'24, Cash and equivalents: $148MQ3'24Q4'24, Cash and equivalents: $85MQ1'25, Cash and equivalents: $96MQ1'25Q2'25, Cash and equivalents: $99MQ3'25, Cash and equivalents: $49MQ3'25Q4'25, Cash and equivalents: $72MQ1'26, Cash and equivalents: $111MQ1'26Q2'26, Cash and equivalents: $108MQ3'26, Cash and equivalents: $76MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 3, 2026.

Encompass Health Corporation Common Stock income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 3, 2026Q2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue1,6101,5971,5871,5451,4781,4581,4551,405+8.9%
Cost of revenue—————————
Gross profit—————————
Research and development—————————
Selling, general and administrative6063586856595255+6.8%
Operating income—————————
Other income (expense)291946732−67.8%
Pretax income258262289258220237239201+17.2%
Income tax5354565545514238+18.9%
Net income150154195146127142152121+18.5%
Diluted EPS ($)1.501.541.93—1.241.391.48—+21.0%
Diluted shares (millions)100100101—102102102——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 3, 2026.

Encompass Health Corporation Common Stock balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 3, 2026Q2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents761081117249999685+56.5%
Short-term investments—————————
Total current assets1,0131,0411,029906870918911887+16.5%
Total assets7,5677,4587,3137,0906,8666,7866,6416,535+10.2%
Total current liabilities927873877836762865856841+21.7%
Long-term debt—————————
Total liabilities4,0053,9963,9463,8143,6793,6983,7043,686+8.9%
Stockholders’ equity2,6812,5982,5222,4382,3742,2802,1592,067+12.9%
Shares outstanding (millions)98999999101101101101—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 3, 2026.

Encompass Health Corporation Common Stock cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 3, 2026Q2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow—————————
Capital expenditures235220162229187157163199+25.3%
Free cash flow (CFO − capex)—————————
Depreciation and amortization9690878682807978+16.1%
Share repurchases587472762525328+132.5%
Dividends paid1919201917171817+10.0%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 26, 2026.

Income statement

Encompass Health Corporation Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 19, 2013FY2011ended Dec 31, 2011filed Feb 23, 2012FY2010ended Dec 31, 2010filed Feb 24, 2011FY2009ended Dec 31, 2009filed Aug 5, 2010FY2008ended Dec 31, 2008filed Aug 5, 2010
Revenue5,9355,3734,8014,3494,0153,5664,6054,2773,9143,643————————
Cost of revenue——————————————————
Gross profit——————————————————
Research and development——————————————————
Selling, general and administrative236209202154170152247220172133133125119118111106105106
Operating income———540560564612555578588486———————
Other income (expense)192016(5)883124363159343—
Pretax income953750607451505353562493496482396387395340243190108—
Income tax193150132100102751161191461641421111310937(741)(3)(70)
Net income56645635227141228435929227124818322232418520989995252
Diluted EPS ($)5.544.463.472.704.112.853.612.932.842.591.912.292.581.671.968.280.772.62
Diluted shares (millions)102102101100100100991009910010110110210810910910396

Balance sheet

Encompass Health Corporation Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 19, 2013FY2011ended Dec 31, 2011filed Feb 23, 2012FY2010ended Dec 31, 2010filed Feb 24, 2011FY2009ended Dec 31, 2009filed Aug 5, 2010FY2008ended Dec 31, 2008filed Aug 5, 2010
Cash and equivalents72856922491866069544162676513330488132
Short-term investments——————————————————
Total current assets906887842717921949756662702655599687580637492406426—
Total assets7,0906,5356,1025,6376,8656,4466,0815,1754,8654,6824,6063,3882,5342,4242,2712,3721,682—
Total current liabilities836841656576749717721673518476426364312301313359391—
Long-term debt——————————————1,2361,4971,641—
Total liabilities3,8143,6863,8053,7754,4664,4444,1483,3563,2483,6153,7062,5911,9591,6711,6821,9872,192—
Stockholders’ equity2,4382,0671,6481,3101,9111,5881,3521,2771,153736611473345291117(85)(898)(1,087)
Shares outstanding (millions)99101100100999998999889908788959593——

Cash flow statement

Encompass Health Corporation Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 19, 2013FY2011ended Dec 31, 2011filed Feb 23, 2012FY2010ended Dec 31, 2010filed Feb 24, 2011FY2009ended Dec 31, 2009filed Aug 5, 2010FY2008ended Dec 31, 2008filed Aug 5, 2010
Operating cash flow———706716705635762658640502445470412343331406227
Capital expenditures736643583584546393372255226178128171195141100636356
Free cash flow (CFO − capex)———122170312263508433463374274275271242268343172
Depreciation and amortization328300274244220203219200184173140108958379736882
Share repurchases1583100064603866454323400———
Dividends paid71636099112112109101928477661600———

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$26M
6 sales by 4 insiders; officers and directors $26M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$48M
18 sales by 6 insiders; officers and directors $48M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 19, 2026Christie Edward M IIIDirectoraward221$126.63$28K9,577Oct 19, 2026
Oct 19, 2026Reidy Christopher RDirectoraward284$126.89$36K18,081Oct 19, 2026
Oct 15, 2026Carmichael Greg DDirectoraward28$0.00—20,377Oct 19, 2026
Oct 15, 2026Williams TerranceDirectoraward28$0.00—16,887Oct 19, 2026
Oct 15, 2026Schlichting Nancy MDirectoraward38$0.00—23,010Oct 19, 2026
Oct 15, 2026Herman Joan EDirectoraward81$0.00—49,724Oct 19, 2026
Oct 15, 2026Christie Edward M IIIDirectoraward11$0.00—9,356Oct 19, 2026
Oct 15, 2026Reidy Christopher RDirectoraward20$0.00—17,797Oct 19, 2026
Oct 15, 2026Hayes Cain ADirectoraward4$0.00—2,100Oct 19, 2026
Oct 15, 2026O'Connor Kevin J.Directoraward18$0.00—11,600Oct 19, 2026
Oct 15, 2026Katz Leslye GDirectoraward81$0.00—49,724Oct 19, 2026
Aug 31, 2026Price Andrew LChief Accounting Officeropen-market sale5,211$120.93$630K69,483Sep 1, 2026
Aug 31, 2026Darby John PatrickEVP, Gen Counsel & Secretaryoption exercise4,858$35.06$170K79,899Sep 1, 2026
Aug 31, 2026Darby John PatrickEVP, Gen Counsel & Secretaryopen-market sale4,858$121.09$588K75,041Sep 1, 2026
Aug 10, 2026Coltharp Douglas EEVP & Chief Financial Officeropen-market sale18,869$125.38$2M50,508Aug 11, 2026
Aug 10, 2026Tarr Mark JPresident & CEO, Directoropen-market sale171,569$125.46$22M269,393Aug 11, 2026
Aug 10, 2026Tarr Mark JPresident & CEO, Directoropen-market sale1,579$126.06$199K267,814Aug 11, 2026
Aug 10, 2026Darby John PatrickEVP, Gen Counsel & Secretaryopen-market sale8,906$125.95$1M75,041Aug 11, 2026
Jul 16, 2026Reidy Christopher RDirectoraward319$112.40$36K17,777Jul 16, 2026
Jul 16, 2026Christie Edward M IIIDirectoraward248$112.43$28K9,345Jul 16, 2026
Jul 15, 2026Reidy Christopher RDirectoraward21$0.00—17,458Jul 16, 2026
Jul 15, 2026Christie Edward M IIIDirectoraward11$0.00—9,097Jul 16, 2026
Jul 15, 2026Williams TerranceDirectoraward29$0.00—16,859Jul 16, 2026
Jul 15, 2026Schlichting Nancy MDirectoraward40$0.00—22,972Jul 16, 2026
Jul 15, 2026O'Connor Kevin J.Directoraward19$0.00—11,582Jul 16, 2026

Full insider history for Encompass Health Corporation Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Encompass Health Corporation, CIK 785161 on EDGAR
Extract generated
November 4, 2026
Withheld
5 line-years whose four quarters do not sum to the filed year: depreciation amortization FY2010, income tax FY2020, revenue FY2020, depreciation amortization FY2021, pretax income FY2021
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2022
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: not filed
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/EHC.json